+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
ContraFect Corporation - logo

ContraFect Corporation is a biotechnology company that develops therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Cystic Fibrosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030 - Product Thumbnail Image

Cystic Fibrosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • Report
  • July 2022
  • 112 Pages
  • Global
From
Systemic Inflammatory Response Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Systemic Inflammatory Response Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Endocarditis - Pipeline Insight, 2024 - Product Thumbnail Image

Endocarditis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Comprehensive Report on ContraFect Corporation, including SWOT, PESTLE and Business Model Canvas - Product Thumbnail Image

Comprehensive Report on ContraFect Corporation, including SWOT, PESTLE and Business Model Canvas

  • SWOT Analysis
  • August 2023
  • 90 Pages
From
Loading Indicator